Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 13/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.46 |
| ▸ | GPR174 | Q9BXC1 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3315467 | 0.86 | MAPT (0.51) | LMNAMAPTRECQLALDH1A1GPR174 | |
| SCHEMBL3313816 | 0.84 | LMNA (0.59) | LMNAMAPTRECQLALDH1A1GPR174 | |
| SCHEMBL3309164 | 0.83 | MAPT (0.49) | LMNAMAPTRECQLALDH1A1GPR174 | |
| SCHEMBL3315189 | 0.82 | MAPT (0.54) | LMNAMAPTRECQLALDH1A1GPR174 | |
| SCHEMBL3316035 | 0.81 | LMNA (0.49) | LMNAMAPTALDH1A1GAAMAPK1 | |
| SCHEMBL3312015 | 0.76 | LMNA (0.64) | LMNAMAPTRECQLALDH1A1GPR174 | |
| SCHEMBL22471138 | 0.75 | MAPT (0.62) | LMNAMAPTRECQLALDH1A1GPR174 | |
| SCHEMBL3316460 | 0.71 | LMNA (0.61) | LMNAMAPTALDH1A1GPR174GAA | |
| SCHEMBL3318884 | 0.71 | ALDH1A1 (0.51) | LMNAMAPTALDH1A1GPR174GAA | |
| SCHEMBL3320231 | 0.71 | ALDH1A1 (0.57) | LMNAMAPTRECQLALDH1A1GPR174 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | LMNA 3341/4885MAPT 2130/4885RECQL 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.